AMPE Ampio Pharmaceuticals Inc

Price (delayed)

$0.1784

Market cap

$40.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.1

Enterprise value

$12.23M

Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment ...

Highlights
The company's debt fell by 37% YoY and by 13% QoQ
Ampio Pharmaceuticals's equity has increased by 33% YoY but it has decreased by 18% from the previous quarter
The quick ratio has decreased by 46% YoY and by 21% QoQ
The net income has declined by 32% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of AMPE
Market
Shares outstanding
227.19M
Market cap
$40.53M
Enterprise value
$12.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$19.04M
EBITDA
-$17.98M
Free cash flow
-$14.9M
Per share
EPS
-$0.1
Free cash flow per share
-$0.07
Book value per share
$0.1
Revenue per share
$0
TBVPS
$0.15
Balance sheet
Total assets
$32.79M
Total liabilities
$10.53M
Debt
$533,000
Equity
$22.25M
Working capital
$24.38M
Liquidity
Debt to equity
0.02
Current ratio
5.41
Quick ratio
5.22
Net debt/EBITDA
1.57
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-63.1%
Return on equity
-87.4%
Return on invested capital
-1,129.9%
Return on capital employed
-69.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPE stock price

How has the Ampio Pharmaceuticals stock price performed over time
Intraday
-11.24%
1 week
10.12%
1 month
4.02%
1 year
-89.98%
YTD
-68.7%
QTD
-62.04%

Financial performance

How have Ampio Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.72M
Net income
-$19.04M
Gross margin
N/A
Net margin
N/A
Ampio Pharmaceuticals's operating income has shrunk by 74% YoY and by 15% QoQ
The net income has declined by 32% year-on-year and by 12% since the previous quarter

Growth

What is Ampio Pharmaceuticals's growth rate over time

Valuation

What is Ampio Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 25% year-on-year and by 11% since the previous quarter
AMPE's price to book (P/B) is 82% less than its last 4 quarters average of 11.1
Ampio Pharmaceuticals's equity has increased by 33% YoY but it has decreased by 18% from the previous quarter

Efficiency

How efficient is Ampio Pharmaceuticals business performance
Ampio Pharmaceuticals's return on invested capital has shrunk by 114% QoQ
The ROE has increased by 22% year-on-year but it has declined by 4.5% since the previous quarter
The return on assets has increased by 21% year-on-year

Dividends

What is AMPE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPE.

Financial health

How did Ampio Pharmaceuticals financials performed over time
The company's total liabilities has surged by 113% YoY but it fell by 9% QoQ
The company's total assets has surged by 51% YoY but it fell by 16% QoQ
The company's debt is 98% lower than its equity
AMPE's debt to equity has dropped by 60% year-on-year
The company's debt fell by 37% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.